170 related articles for article (PubMed ID: 32590441)
1. Cases of coronavirus disease-2019 in HIV-infected transgender women.
Adachi E; Saito M; Ikeuchi K; Hoshina T; Yotsuyanagi H
AIDS; 2020 Jul; 34(9):1435-1436. PubMed ID: 32590441
[No Abstract] [Full Text] [Related]
2. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
3. Advance of promising targets and agents against COVID-19 in China.
Duan Y; Zhu HL; Zhou C
Drug Discov Today; 2020 May; 25(5):810-812. PubMed ID: 32198066
[No Abstract] [Full Text] [Related]
4. Treatment and Outcome of a Patient With Lung Cancer Infected With Severe Acute Respiratory Syndrome Coronavirus-2.
Zhang H; Xie C; Huang Y
J Thorac Oncol; 2020 May; 15(5):e63-e64. PubMed ID: 32147577
[No Abstract] [Full Text] [Related]
5. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
6. Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient.
Gómez-Enjuto S; Hernando-Requejo V; Lapeña-Motilva J; Ogando-Durán G; Fouz-Ruiz D; Domingo-García J; Rodríguez-García E; Cemillán-Fernández CA
Seizure; 2020 Aug; 80():157-158. PubMed ID: 32574838
[No Abstract] [Full Text] [Related]
7. HIV 101: fundamentals of antiretroviral therapy.
Saag MS
Top Antivir Med; 2019 Sep; 27(3):123-127. PubMed ID: 31634859
[TBL] [Abstract][Full Text] [Related]
8. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
[TBL] [Abstract][Full Text] [Related]
9. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China.
Zhu F; Cao Y; Xu S; Zhou M
J Med Virol; 2020 Jun; 92(6):529-530. PubMed ID: 32160316
[No Abstract] [Full Text] [Related]
10. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
Orkin C; DeJesus E; Sax PE; Arribas JR; Gupta SK; Martorell C; Stephens JL; Stellbrink HJ; Wohl D; Maggiolo F; Thompson MA; Podzamczer D; Hagins D; Flamm JA; Brinson C; Clarke A; Huang H; Acosta R; Brainard DM; Collins SE; Martin H; ;
Lancet HIV; 2020 Jun; 7(6):e389-e400. PubMed ID: 32504574
[TBL] [Abstract][Full Text] [Related]
11. Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Acosta RK; Willkom M; Martin R; Chang S; Wei X; Garner W; Lutz J; Majeed S; SenGupta D; Martin H; Quirk E; White KL
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30803969
[TBL] [Abstract][Full Text] [Related]
12. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
13. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.
Tadolini M; Codecasa LR; García-García JM; Blanc FX; Borisov S; Alffenaar JW; Andréjak C; Bachez P; Bart PA; Belilovski E; Cardoso-Landivar J; Centis R; D'Ambrosio L; Luiza De Souza-Galvão M; Dominguez-Castellano A; Dourmane S; Fréchet Jachym M; Froissart A; Giacomet V; Goletti D; Grard S; Gualano G; Izadifar A; Le Du D; Marín Royo M; Mazza-Stalder J; Motta I; Ong CWM; Palmieri F; Rivière F; Rodrigo T; Silva DR; Sánchez-Montalvá A; Saporiti M; Scarpellini P; Schlemmer F; Spanevello A; Sumarokova E; Tabernero E; Tambyah PA; Tiberi S; Torre A; Visca D; Zabaleta Murguiondo M; Sotgiu G; Migliori GB
Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32457198
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
[TBL] [Abstract][Full Text] [Related]
15. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
Cheng CY; Lee YL; Chen CP; Lin YC; Liu CE; Liao CH; Cheng SH
J Microbiol Immunol Infect; 2020 Jun; 53(3):488-492. PubMed ID: 32331982
[TBL] [Abstract][Full Text] [Related]
16. Race to find COVID-19 treatments accelerates.
Kupferschmidt K; Cohen J
Science; 2020 Mar; 367(6485):1412-1413. PubMed ID: 32217705
[No Abstract] [Full Text] [Related]
17. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL; Deeks ED
Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
[TBL] [Abstract][Full Text] [Related]
18. Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
Calza L; Borderi M; Colangeli V; Miani T; Nuti B; Bon I; Lazzarotto T; Viale P
AIDS; 2022 Jan; 36(1):153-155. PubMed ID: 34873095
[No Abstract] [Full Text] [Related]
19. The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19.
Danion F; Ruch Y; Fourtage M; Kaeuffer C; Greigert V; Lefebvre N; Muller J; Nai T; Hansmann Y
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513798
[No Abstract] [Full Text] [Related]
20. Skin manifestations associated with the new coronavirus SARS-CoV-2 disease.
Redondo-Sendino Á; González Sánchez IC; de Victoria Fernández B
Med Clin (Barc); 2020 Nov; 155(9):414-415. PubMed ID: 32873395
[No Abstract] [Full Text] [Related]
[Next] [New Search]
